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Introduction: Exertional and/or environmental heat stroke ( ES) and exertional rha bdomyolysis (ER) has been reported in patients with diagnosis of Malignant Hyperthermia (MH). MH is a lifethreatening pharmacogenetic disorder caused b y mutations in the ryan odine receptor type 1 gene (RYR1) encoding skeletal muscle calcium release channel. Our goal is to id entify RYR1 mutations associated with enhanced suscep tibility to EHS/ER/MH by enrolling subjects diagnosed with these conditions and performing genetic screen ing. We also proposed to evaluate the ability of AICAR to prevent the MH response in MHS mice and pigs. Body: During the project period, 37 patients (out of 45 proposed) with a history of EHS/ER or MH were e nrolled in this study. The RYR1 gene was screened in t hese individuals. RYR1 mutations and variants were identified in 13 of the 37 enrolled patients (see Table 1 attached). Four well known disea se causative MH mutat ions (Arg163Cys, Gly2434Arg, Arg2454Cys an d Arg2163His), two previously publish ed MH-associated mutations and tw o novel variants were identified in the RYR1 gene. Of the four common mutations, the Arg2454Cys was id entified in an African American patient with a positiv e CHCT (validated diagnostic t est for MH susceptibility) and a history of ER. Since the Arg2454Cys mutation is characterized as causative for MH, identification of this mutation in a subject with ER further strengthens a link between MH and ER. A new variant, Gly4820Arg, was found in a family with a history of a dea th due to an awake MH-like event.
To date, 37 patients diagnosed with MHS, ER and/or EHS and their family members have been enrolled (Table 1) . Of th ese, 27 are index cases and 10 are first degree relatives of two of the index cases, BU-05 and BU-12 (Fig. 1) . Enrollment of family members is important for studying the genotype and phen otype relationships, and to understand the pa thogenic significance of familial variants.
RYR1 gene mutations and variants have been found in 8 index cases, which account for 30% of the index cases. One patient, who died of an awake MH-like episode but was known to be MH susceptible, had a Ph e41Ser novel RYR1 variant and a Gly2434 Arg known MH-causative mutation. Of these two variants, t he Gly2434Arg is one of the most common pathogenic mutations in the RYR1 gene. The presence of the second variant may have contributed to the fatal outcome in th is case; however the fun ctional significance of the second varia nt requires further studies. Another novel variant, Gly4820Arg, was fou nd in the fat her of a child who had the same variant and died of an awake MH-like episo de. This fa ther was subsequently diagnosed MH susceptible by positive CHCT, and was further diagnosed with central core disease based on his muscle histopatholog y. Interestingly, another mutation at the same position, Gly4820Trp, was reported in association with MH susceptibility (Robinson et al., 2006) .
Three patients who presented with ER, and who were dia gnosed MH susceptible by positive CHCT, did not have any RYR1 vari ants after complete scr eening of the gene. These patients will be further analyzed for CACNA1 S and CASQ1 gene mutations. The RYR1 gene screening continues in 16 other patients. However we found that AICAR requi res extremely hig h concentrations and hen ce we established a collaboration with Prof. Gennaro Piccialli to sy nthesize and test AICAR derivative s to find a more potent analog. We have a very good candidate (structure shown to the right ) that is much more potent in [ 3 H]ryanodine binding assays than AICAR. W e are preparing to test it in the MH mice and then in the MHS pigs which, as discussed b elow, are not r escued by AICAR, most likely due to our i nability to achieve an effective concentration. We found that AICAR, when administered as a pretreatment or as a rescue dru g, was not effective as a treatment for heat-induced MH in the MH susceptible swine. This findin g appeared to be in conflict with data obtained in the MH susceptible transgenic YS mouse model. We hypothesized that in the pig model AICAR (600mg/kg IV) may n ot achieve an effective concentration in the swine skeletal muscle. To test this po ssibility, we exa mined the effect of AICAR on isolated muscle preparations from the MHS pigs.
Six MHS s wine were anesthetized as previously describ ed with a total intravenous propof ol infusion and euthanized at the end of the already approve d in vivo protocol. While receiving propofol general anesthesia during the approved portion o f the protocol, a 2 inch incision was made on the ventral su rface of the swine's lo wer limb. The skin was shaved, cleaned and prepped with alcohol b efore incision. Emplo ying sterile technique, a number 15 scalpel blade was used to incise the skin, while surgical scissors and forceps were used to expose the underlying muscle. The muscle was dissected and excised using scalpel, surgical scissors and forceps, and placed on tension in two specialized clamps. The muscle specimen was measured 1.0 inch by 0.5 inch, and it was immediately placed in a Krebs-Ringer solution. The muscle was taken to an other laboratory for analysis in the in vitro contracture test (Table 2) , using the standard procedures for the performance of the caffeine halothane contracture test as described by the North American Malignant Hyperthermia Group (Larach 1989) . The results are shown in Table 2. AICAR at 1mM and 10mM did not alter basal tension of muscle strips, (P = 0.96 and 0.86) when compared to baseline tension of untreated control strips. Similarly AICAR (1 and 10mM) did not significantly alter halothane-or caffeine-induced contractures.
The results (Table 2) from the in vitro studies from MHS swine indicate that AICAR had no effect at both low and high concentrations on muscle tension development in basal conditions, nor did AICAR influence responses induced by caffeine and halot hane challenges. This is consistent with the previous report that AICAR is ineffective when ad ministered intravenously in the MHS pig model.
Key accomplishments:
 Further support that RyR1 mutations underlie ER/EHS  Publication of AICAR mechanism of action to prevent EHS  Identification of AICAR derivative with higher potency  Case report publication of awake MH
Reportable Outcomes:
 37 patients diagnosed with MHS, ER and/or EHS and their family members have been enrolled (Table 1) . Of these, 27 are index cases and 10 are first degree relatives of two of the index cases.  RYR1 gene mutations and variants have been found in 8 index cases which account for 30% of the index cases.  One patient who died of an awake MH-like episode had two RYR1 gene variants, Phe41Ser and Gly2434Arg. Of these two variants, the Gly2434Arg is one of the most common pathogenic mutations in the RYR1 gene.  Two novel variants, Gly4820Trp and Phe41Ser were found in two independent cases.  Published: Lanner, J., Georgiou, D.K., Dagnino-Acosta, A., Ainbinder, A., Cheng, Q., Joshi, A., Chen, Z., Yarotskyy, V., Oakes, J., Lee, C.S., Monroe, T., Santillan, A., Dong, K., Goodyear, L., Isma ilov, I., Rod ney, G.G., Dirksen, R., and Ha milton, S. AICAR Prevents Heat Induced Malignant Hyperthermia in RyR1 Mutant Mice Independe nt of AMPK Activation, Nature Medicine,18: 244 -251, 2012 PMID: 22231 556 [PubMed -as supplied by publisher.  We discovered an AICAR derivative that is more potent that AICAR  AICAR at 1mM and 10mM did not alter basal tension of pig muscle strips, (P = 0.96 and 0.86) when compared to baseline tension of untreated control strips.  Similarly, AICAR (1 and 10mM) did not significantly alter halothane-or caffeine-induced contractures.  AICAR is ineffective when administered intravenously in the MHS pig model, but the more potent derivative will now be tested  Manuscript in print in Anesthesia and Analgesia. "Death in the Emergency Department:
An unrecognized awake MH-like reaction in a six year old".
Conclusions:
 RYR1 mutations underlie a significant number of cases of exercise induced rhabdomyolysis and environmental heat stroke.  AICAR prevents EHS in mice heterozygous for RYR1 mutation associated with MH in humans but not in pigs that are homozygous for a different mutation.  Derivatives of AICAR may be more potent for preventing EHS/ER than AICAR
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Results

Index or Family members
Results of genetic screening Data were analyzed using two way ANOVA and are presented as Mean ± SEM, n = number of muscle strips tested. Muscle strips from MHS swine were mounted in an organ bath and after initial equilibration period (10-15 min) muscle strips were treated with distilled water with and without (control) AICAR (1 and 10mM). Basal tension of strips was recorded continuously up to 90mins. After 90mins period, muscle strips were treated with either 3% halothane or 2mM caffeine. 2.11 ± 0.11 n = 18
Treatment
1.68 ± 0.09 n = 18
1.72 ± 0.14 n = 9
2.99 ± 0.46 n = 9
1.37 ± 0.28 n = 7
10mM AICAR 4.6 ± 0.95 n= 18
1.82 ± 0.12 n = 18
1.30 ± 0.13 n = 18
1.33 ± 0.15 n = 9
2.93 ± 0.32 n = 9
1.43 ± 0.18 n = 7
